Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Vaccine ; 37(36): 5414-5421, 2019 08 23.
Artigo em Inglês | MEDLINE | ID: mdl-31331774

RESUMO

The Global Pertussis Initiative (GPI) is an expert scientific forum that publishes consensus recommendations for pertussis monitoring, prevention, and treatment across many regions of the world. Here, we report on the regional 2017 GPI meeting on the Americas, focusing on Latin America. Information on current pertussis epidemiology, surveillance, vaccine strategies, diagnostic capabilities, disease awareness, and major local obstacles was presented by researchers from Argentina, Brazil, Colombia, Costa Rica, El Salvador, Mexico, Peru, Puerto Rico, Uruguay, and Venezuela. Pertussis outbreaks have occurred during the last decade in the majority of participant countries and have been followed by improvements in surveillance. In the countries that introduced maternal immunization during pregnancy, a reduction in the infant case fatality rate has been detected. All countries need to maintain and improve pertussis surveillance to reach primary vaccination coverage >90%. Moreover, countries without maternal immunization programs should strongly consider them.


Assuntos
Bordetella pertussis/patogenicidade , Coqueluche/epidemiologia , Coqueluche/microbiologia , Argentina/epidemiologia , Bordetella pertussis/imunologia , Brasil/epidemiologia , Colômbia/epidemiologia , Costa Rica/epidemiologia , Humanos , América Latina/epidemiologia , México/epidemiologia , Peru/epidemiologia , Período Pós-Parto , Porto Rico/epidemiologia , Uruguai/epidemiologia , Vacinação/métodos , Venezuela/epidemiologia , Coqueluche/prevenção & controle
2.
Clin Vaccine Immunol ; 23(11): 842-850, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27655886

RESUMO

Pertussis is a severe respiratory disease caused by infection with the bacterial pathogen Bordetella pertussis The disease affects individuals of all ages but is particularly severe and sometimes fatal in unvaccinated young infants. Other Bordetella species cause diseases in humans, animals, and birds. Scientific, clinical, public health, vaccine company, and regulatory agency experts on these pathogens and diseases gathered in Buenos Aires, Argentina from 5 to 8 April 2016 for the 11th International Bordetella Symposium to discuss recent advances in our understanding of the biology of these organisms, the diseases they cause, and the development of new vaccines and other strategies to prevent these diseases. Highlights of the meeting included pertussis epidemiology in developing nations, genomic analysis of Bordetella biology and evolution, regulation of virulence factor expression, new model systems to study Bordetella biology and disease, effects of different vaccines on immune responses, maternal immunization as a strategy to prevent newborn disease, and novel vaccine development for pertussis. In addition, the group approved the formation of an International Bordetella Society to promote research and information exchange on bordetellae and to organize future meetings. A new Bordetella.org website will also be developed to facilitate these goals.


Assuntos
Bordetella pertussis/imunologia , Bordetella pertussis/fisiologia , Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Animais , Argentina/epidemiologia , Proteínas da Membrana Bacteriana Externa/imunologia , Humanos , Lactente , Vacinação , Fatores de Virulência de Bordetella/imunologia , Coqueluche/epidemiologia , Coqueluche/microbiologia
3.
Hum Vaccin ; 6(11): 876-80, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20980794

RESUMO

Pertussis remains endemic across the world, with an estimated 279,000 deaths in 2002, the majority in infants under 1 year of age. Worldwide epidemiologic data indicates increasing infection rates in older children and adults, which act as a source of infection to young infants. The Global Pertussis Initiative (GPI) is an expert scientific forum, which has published consensus recommendations for the monitoring, prevention, and treatment of the disease. This paper reports the proceedings of a regional meeting, held in Costa Rica in December 2008. The meeting gathered information on regional epidemiological, diagnostic capabilities and the ability to introduce GPI recommended vaccine strategies in Latin America. The capacity of Latin American countries to conduct vaccination programs is high and there is considerable government support. Whole-cell pertussis vaccines are used across Latin America, which appear to be quite effective. A 4-dose schedule is typically used (2, 4, 6, and 18 months), and a booster given at 4 to 6 years of age, with coverage often above 90%, but with regions of low coverage due to political and geographical difficulties. Adequate surveillance is lacking in many countries, giving insufficient data to guide vaccination policy. Improvements are being made, with countries such as Costa Rica, Panama, and Argentina introducing polymerase chain reaction (PCR) diagnosis. Those countries that do not currently use a preschool booster should launch one. Implementing vaccination programs in adolescents and/or adults to reduce exposure to infants would be beneficial and possible in most countries, given their current infrastructure.


Assuntos
Doenças Transmissíveis Emergentes/epidemiologia , Doenças Transmissíveis Emergentes/prevenção & controle , Vacina contra Coqueluche/imunologia , Coqueluche/epidemiologia , Coqueluche/prevenção & controle , Humanos , Imunização Secundária/métodos , América Latina/epidemiologia , Vacina contra Coqueluche/administração & dosagem , Vigilância da População , Vacinação/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA